Table 3.
Antimicrobial resistance distribution of Shigella isolates recovered from pediatric patients in Mashhad, Iran, 2019–2022.
| Antibiotics |
S. sonnei No. (%), n = 64 | S. flexneri No. (%), n = 18 | p-value | Cramér's V (95 % CI) | S. boydii No. (%), n = 1 | Total of Shigella Strains No. (%), n = 83 |
|---|---|---|---|---|---|---|
| Non-fluroquinolones | ||||||
| AMP | 55 (85.9) | 14 (77.7) | 0.4 | – | 1 (100.0) | 70 (84.3) |
| TET | 53 (82.8) | 16 (88.8) | 0.53 | – | 1 (100.0) | 70 (84.3) |
| SXT | 56 (87.5) | 11 (61.1) | 0.01 | 0.28 (0.06, 0.51) | 1 (100.0) | 68 (81.9) |
| AZT | 44 (68.7) | 5 (27.7) | 0.02 | 0.34 (0.13, 0.52) | 1 (100.0) | 50 (60.2) |
| CTX | 15 (23.4) | 8 (44.4) | 0.08 | 0.19 (0.01, 0.42) | 0 (00.0) | 23 (27.7) |
| CRO | 2 (3.1) | 5 (27.7) | 0.001 | 0.36 (0.07, 0.61) | 0 (00.0) | 7 (8.4) |
| MEM | 0 (00.0) | 0 (00.0) | – | – | 0 (00.0) | 0 (00.0) |
| Fluroquinolones | ||||||
| NA | 32 (50.0) | 6 (33.3) | 0.21 | – | 0 (00.0) | 38 (45.8) |
| CIP | 8 (14.0) | 2 (11.1) | 0.33 | – | 0 (00.0) | 10 (12.0) |
| OFL | 4 (6.2) | 1 (2.2) | 0.91 | 0 (00.0) | 5 (6.0) | |
| NOR | 2 (3.1) | 1 (5.5) | 0.62 | 0 (00.0) | 3 (3.6) | |
| LEV | 1 (1.5) | 1 (5.5) | – | 0 (00.0) | 1 (2.4) | |
| FQ resistance | 32 (50.0) | 6 (33.3) | 0.21 | 0.12 (0.006, 0.34) | 0 (00.0) | 38 (45.8) |
| MDR | 60 (93.8) | 13 (72.2) | 0.02 | 0.28 (0.03, 0.54) | 1 (100.0) | 74 (89.1) |
Abbreviations: AMP, ampicillin; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; AZT, azithromycin; CTX, cefotaxime; CRO, ceftriaxone MEM, Meropenem; NA, nalidixic acid; CIP, ciprofloxacin; OFL, ofloxacin; NOR, norfloxacin; LEV, levofloxacin; FQ, Fluroquinolones; MDR, Multidrug resistance.